Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B.

Sugahara S, Ichida T, Yamagiwa S, Ishikawa T, Uehara K, Yoshida Y, Yang XH, Nomoto M, Watanabe H, Abo T, Asakura H

Hepatology research : the official journal of the Japan Society of Hepatology1 Dec 2002Cited by 20 (Europe PMC)

PMID12479932DOI10.1016/s1386-6346(02)00145-6PepBankPUB-12479932

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialEfficacy outcome
In seven adults with chronic hepatitis B, two patients (28.6%) had normalized alanine aminotransferase forty-eight weeks after thymosin alpha1 treatment.
In plain wordsIn seven people with chronic hepatitis B, two had normal liver enzyme levels forty-eight weeks after thymosin alpha1 treatment.
Peptide
Thymosin alpha-1
Outcome
DecreaseALT normalization 48 weeks after treatment
Study
n = 7
Outcome group
Liver fat and liver function · Liver
Studied dose
1.2 mg · 24 weeksAs given in this study (human).
Measurements
Patients with normalized ALT
28.6%
48 weeks after treatment
Source sentences
Summary
Forty-eight weeks after T-alpha1 treatment, two patients (28.6%) showed normalized alanine aminotransferase
2 context sentences(design, population, supporting numbers)
Summary · context
Seven patients with CHB were treated with 1.2 mg of T-alpha1 for 24 weeks.
Summary · context
Peripheral blood lymphocytes (PBL) and intrahepatic lymphocytes were analyzed by flow cytometry.
Report a problemFND-1247993201
02HumanNon-randomized trialEfficacy outcome
In seven adults with chronic hepatitis B, two patients (28.6%) had serum HBV-DNA that fell to an undetectable level forty-eight weeks after thymosin alpha1 treatment.
In plain wordsIn seven people with chronic hepatitis B, two had no detectable hepatitis B virus in blood forty-eight weeks after thymosin alpha1 treatment.
Peptide
Thymosin alpha-1
Outcome
DecreaseSerum HBV-DNA undetectable 48 weeks after treatment
Study
n = 7
Outcome group
Antiviral activity · Infection
Studied dose
1.2 mg · 24 weeksAs given in this study (human).
Measurements
Patients with undetectable HBV-DNA
28.6%
48 weeks after treatment
Source sentences
Summary
Forty-eight weeks after T-alpha1 treatment, two patients (28.6%) showed normalized alanine aminotransferase and decreased HBV-DNA to undetectable level from serum.
2 context sentences(design, population, supporting numbers)
Summary · context
Seven patients with CHB were treated with 1.2 mg of T-alpha1 for 24 weeks.
Summary · context
Peripheral blood lymphocytes (PBL) and intrahepatic lymphocytes were analyzed by flow cytometry.
Report a problemFND-1247993202
03HumanNon-randomized trialEfficacy outcome
In seven adults with chronic hepatitis B, the histology activity index score decreased significantly after thymosin alpha1 treatment.
In plain wordsIn seven people with chronic hepatitis B, liver tissue damage scores fell after thymosin alpha1 treatment.
Peptide
Thymosin alpha-1
Outcome
DecreaseHistology activity index score
Study
n = 7
Outcome group
Liver fat and liver function · Liver
Studied dose
1.2 mg · 24 weeksAs given in this study (human).
Source sentences
Summary
The histology activity index score significantly decreased (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Seven patients with CHB were treated with 1.2 mg of T-alpha1 for 24 weeks.
Summary · context
Peripheral blood lymphocytes (PBL) and intrahepatic lymphocytes were analyzed by flow cytometry.
Report a problemFND-1247993203
04HumanNon-randomized trialMechanism
In seven adults with chronic hepatitis B, serum interferon-gamma was not elevated after thymosin alpha1 treatment.
In plain wordsIn seven people with chronic hepatitis B, thymosin alpha1 did not raise interferon-gamma in the blood.
Peptide
Thymosin alpha-1
Outcome
No significant changeSerum interferon-gamma
Study
n = 7
Outcome group
Immune response · Immune and inflammation
Studied dose
1.2 mg · 24 weeksAs given in this study (human).
Source sentences
Summary
Although elevated serum interferon (IFN)-gamma was not observed
2 context sentences(design, population, supporting numbers)
Summary · context
Seven patients with CHB were treated with 1.2 mg of T-alpha1 for 24 weeks.
Summary · context
Peripheral blood lymphocytes (PBL) and intrahepatic lymphocytes were analyzed by flow cytometry.
Report a problemFND-1247993204
05HumanNon-randomized trialMechanism
In seven adults with chronic hepatitis B, IFN-gamma producing Th1-type CD4+ peripheral blood lymphocytes appeared to increase after thymosin alpha1 treatment.
In plain wordsIn seven people with chronic hepatitis B, certain interferon-producing blood immune cells seemed to increase after thymosin alpha1 treatment.
Peptide
Thymosin alpha-1
Outcome
IncreaseIFN-gamma producing Th1-type CD4+ peripheral blood lymphocytes
Study
n = 7
Outcome group
Immune response · Immune and inflammation
Studied dose
1.2 mg · 24 weeksAs given in this study (human).
Source sentences
Summary
IFN-gamma producing Th1-type CD4(+) PBL appeared to be increased.
2 context sentences(design, population, supporting numbers)
Summary · context
Seven patients with CHB were treated with 1.2 mg of T-alpha1 for 24 weeks.
Summary · context
Peripheral blood lymphocytes (PBL) and intrahepatic lymphocytes were analyzed by flow cytometry.
Report a problemFND-1247993205
06HumanNon-randomized trialMechanism
In seven adults with chronic hepatitis B, CD56+ natural killer T cells in peripheral blood did not increase after thymosin alpha1 treatment.
In plain wordsIn seven people with chronic hepatitis B, thymosin alpha1 did not raise natural killer T cells in the blood.
Peptide
Thymosin alpha-1
Outcome
No significant changeCD56+ NKT cells in peripheral blood
Study
n = 7
Outcome group
Immune response · Immune and inflammation
Studied dose
1.2 mg · 24 weeksAs given in this study (human).
Source sentences
Summary
CD56(+) natural killer T (NKT) cells in PBL did not increase
2 context sentences(design, population, supporting numbers)
Summary · context
Seven patients with CHB were treated with 1.2 mg of T-alpha1 for 24 weeks.
Summary · context
Peripheral blood lymphocytes (PBL) and intrahepatic lymphocytes were analyzed by flow cytometry.
Report a problemFND-1247993206
07HumanNon-randomized trialMechanism
In seven adults with chronic hepatitis B, CD56+ natural killer T cells in the liver remained significantly augmented even at the end of thymosin alpha1 treatment (P<0.05).
In plain wordsIn seven people with chronic hepatitis B, natural killer T cells in the liver stayed raised through thymosin alpha1 treatment.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD56+ NKT cells in liver
Study
n = 7
Outcome group
Immune response · Immune and inflammation
Studied dose
1.2 mg · 24 weeksAs given in this study (human).
Source sentences
Summary
these cells in the liver remained significantly augmented even at the end of treatment (P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Seven patients with CHB were treated with 1.2 mg of T-alpha1 for 24 weeks.
Summary · context
Peripheral blood lymphocytes (PBL) and intrahepatic lymphocytes were analyzed by flow cytometry.
Report a problemFND-1247993207
08HumanNon-randomized trialMechanism
In seven adults with chronic hepatitis B, CD57+ natural killer T cells increased slightly after thymosin alpha1 treatment.
In plain wordsIn seven people with chronic hepatitis B, a type of natural killer T cell rose slightly after thymosin alpha1 treatment.
Peptide
Thymosin alpha-1
Outcome
IncreaseCD57+ NKT cells
Study
n = 7
Outcome group
Immune response · Immune and inflammation
Studied dose
1.2 mg · 24 weeksAs given in this study (human).
Source sentences
Summary
CD57(+) NKT cells slightly increased
2 context sentences(design, population, supporting numbers)
Summary · context
Seven patients with CHB were treated with 1.2 mg of T-alpha1 for 24 weeks.
Summary · context
Peripheral blood lymphocytes (PBL) and intrahepatic lymphocytes were analyzed by flow cytometry.
Report a problemFND-1247993208
09HumanNon-randomized trialMechanism
In seven adults with chronic hepatitis B, the ratio of CD4+ to CD8+ T cells in the liver decreased after thymosin alpha1 treatment.
In plain wordsIn seven people with chronic hepatitis B, the balance of helper to killer T cells in the liver shifted after thymosin alpha1 treatment.
Peptide
Thymosin alpha-1
Outcome
DecreaseCD4+/CD8+ T-cell ratio in liver
Study
n = 7
Outcome group
Immune response · Immune and inflammation
Studied dose
1.2 mg · 24 weeksAs given in this study (human).
Source sentences
Summary
the ratio of CD4(+) T/CD8(+) T cells decreased in the liver.
2 context sentences(design, population, supporting numbers)
Summary · context
Seven patients with CHB were treated with 1.2 mg of T-alpha1 for 24 weeks.
Summary · context
Peripheral blood lymphocytes (PBL) and intrahepatic lymphocytes were analyzed by flow cytometry.
Report a problemFND-1247993209
10HumanNon-randomized trialMechanism
In seven adults with chronic hepatitis B, thymosin alpha1 did not influence double-positive CD4+8+ T cells.
In plain wordsIn seven people with chronic hepatitis B, thymosin alpha1 did not change one type of immature T cell.
Peptide
Thymosin alpha-1
Outcome
No significant changeDouble-positive CD4+8+ T cells
Study
n = 7
Outcome group
Immune response · Immune and inflammation
Studied dose
1.2 mg · 24 weeksAs given in this study (human).
Source sentences
Summary
T-alpha1 did not influence either double-positive CD4(+)8(+) T or double-negative CD4(-)8(-) cell subsets.
2 context sentences(design, population, supporting numbers)
Summary · context
Seven patients with CHB were treated with 1.2 mg of T-alpha1 for 24 weeks.
Summary · context
Peripheral blood lymphocytes (PBL) and intrahepatic lymphocytes were analyzed by flow cytometry.
Report a problemFND-1247993210
11HumanNon-randomized trialMechanism
In seven adults with chronic hepatitis B, thymosin alpha1 did not influence double-negative CD4-8- cell subsets.
In plain wordsIn seven people with chronic hepatitis B, thymosin alpha1 did not change another type of immature T cell.
Peptide
Thymosin alpha-1
Outcome
No significant changeDouble-negative CD4-8- T-cell subset
Study
n = 7
Outcome group
Immune response · Immune and inflammation
Studied dose
1.2 mg · 24 weeksAs given in this study (human).
Source sentences
Summary
T-alpha1 did not influence either double-positive CD4(+)8(+) T or double-negative CD4(-)8(-) cell subsets.
2 context sentences(design, population, supporting numbers)
Summary · context
Seven patients with CHB were treated with 1.2 mg of T-alpha1 for 24 weeks.
Summary · context
Peripheral blood lymphocytes (PBL) and intrahepatic lymphocytes were analyzed by flow cytometry.
Report a problemFND-1247993211

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

PepBank is a research reference. Talk to a doctor before you use any peptide.